Citations

Clear

1446 citation(s) found for "Howard, F".

Imaging of the Chest, vols. 1 and II
Jolles, Howard

Mayo Clinic

American Journal of Roentgenology | December 19, 2008 | Volume: 192 | Issue: 1 | Pages: W38-W38

10.2214/ajr.08.1548 Get It

Robot-Assisted Laparoscopic Excision and Ureteroureterostomy for Congenital Midureteral Stricture
Thiel, David D. , Badger, William J., Winfield, Howard N.

Mayo Clinic

Journal of Endourology | December 19, 2008 | Volume: 22 | Issue: 12 | Pages: 2667-2670

10.1089/end.2008.9692 | PMID 19099515 Get It

Synapses are regulated by the cytoplasmic tyrosine kinase Fer in a pathway mediated by p120catenin, Fer, SHP-2, and β-catenin
Lee, Seung-Hye, Peng, I‐Feng , Ng, Yu Gie, Yanagisawa, Masahiro, Elia, Lisa P. , Balsamo, Janne, Lilien, Jack, Anastasiadis, Panos Z. , Ullian, Erik M. , Reichardt, Louis F. , Ng, Yu‐Gie, Bamji, Shernaz X.

Mayo Clinic

The Journal of Cell Biology | December 1, 2008 | Volume: 183 | Issue: 5 | Pages: 893-908

10.1083/jcb.200807188 | PMID 19047464 Get It

Localization of presynaptic components to synaptic sites is critical for hippocampal synapse formation. Cell adhesion–regulated signaling is important for synaptic development and function, but little is known about differentiation of the presynaptic compartment. In this study, we describe a pathway that promotes presynaptic development involving p120catenin (p120ctn), the cytoplasmic tyrosine kinase Fer, the protein phosphatase SHP-2, and β-catenin. Presynaptic Fer depletion prevents localization of active zone constituents and synaptic vesicles and inhibits excitatory synapse formation and synaptic transmission. Depletion of p120ctn or SHP-2 similarly disrupts synaptic vesicle localization with active SHP-2, restoring synapse formation in the absence of Fer. Fer or SHP-2 depletion results in elevated tyrosine phosphorylation of β-catenin. β-Catenin overexpression restores normal synaptic vesicle localization in the absence of Fer or SHP-2. Our results indicate that a presynaptic signaling pathway through p120ctn, Fer, SHP-2, and β-catenin promotes excitatory synapse development and function.
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis
Viglietta, Vissia , Iglesias, Antonio , Merbl, Yifat , Izquierdo, Guillermo , Lucas, Miguel , Basso, Alexandre S. , Khoury, Samia J. , Lucchinetti, Claudia F. , Cohen, Irun R. , Weiner, Howard L. , Quintana, Francisco Javier , Farez, Mauricio

Mayo Clinic

Proceedings of the National Academy of Sciences | November 21, 2008 | Volume: 105 | Issue: 48 | Pages: 18889-18894

10.1073/pnas.0806310105 | PMID 19028871 Get It

Multiple sclerosis (MS) is a chronic relapsing disease of the central nervous system (CNS) in which immune processes are believed to play a major role. To date, there is no reliable method by which to characterize the immune processes and their changes associated with different forms of MS and disease progression. We performed antigen microarray analysis to characterize patterns of antibody reactivity in MS serum against a panel of CNS protein and lipid autoantigens and heat shock proteins. Informatic analysis consisted of a training set that was validated on a blinded test set. The results were further validated on an independent cohort of relapsing–remitting (RRMS) samples. We found unique autoantibody patterns that distinguished RRMS, secondary progressive (SPMS), and primary progressive (PPMS) MS from both healthy controls and other neurologic or autoimmune driven diseases including Alzheimer's disease, adrenoleukodystropy, and lupus erythematosus. RRMS was characterized by autoantibodies to heat shock proteins that were not observed in PPMS or SPMS. In addition, RRMS, SPMS, and PPMS were characterized by unique patterns of reactivity to CNS antigens. Furthermore, we examined sera from patients with different immunopathologic patterns of MS as determined by brain biopsy, and we identified unique antibody patterns to lipids and CNS-derived peptides that were linked to each type of pathology. The demonstration of unique serum immune signatures linked to different stages and pathologic processes in MS provides an avenue to monitor MS and to characterize immunopathogenic mechanisms and therapeutic targets in the disease.
Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
Arkenau, Hendrik‐Tobias , Arnold, Dirk , Cassidy, Jim , Díaz‐Rubio, Eduardo , Douillard, Jean‐Yves , Höchster, Howard S. , Martoni, Andrea , Hinke, Axel , Schmiegel, Wolff , Porschen, Rainer, Grothey, Axel , Schmoll, Hans‐Joachim

Mayo Clinic

Journal of Clinical Oncology | November 18, 2008 | Volume: 26 | Issue: 36 | Pages: 5910-5917

10.1200/jco.2008.16.7759 | PMID 19018087 Get It

Purpose Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer. This meta-analysis compared the efficacy of CAP/OX compared with infusional FU/OX. Patients and Methods This analysis compared all published CAP/OX versus infusional FU/OX regimens. A total of 3,494 patients (FU, n = 1,737; CAP, n = 1,757) were analyzed for response rate (RR), progression-free (PFS), overall survival (OS), and toxicity. Results The fixed-effect pooled estimate for RR showed higher RR for FU-based regimens (Odds ratio [OR] = 0.85; 95% CI, 0.74 to 0.97; P = .02) whereas the analysis of chemotherapy-only trials, excluding the bevacizumab containing NO16966 and TREE 2 trials, led to an OR of 0.74 (95% CI, 0.60 to 0.92; P = .007). However, for PFS (hazard ratio [HR] = 1.04; 95% CI, 0.96 to 1.12; P = .17) and OS (HR = 1.04; 95% CI, 0.95 to 1.12; P = .41) all models suggested similar outcome within the range of noninferiority. Grade 3/4 toxicities (thrombocytopenia—HR = 2.07, 95% CI, 1.42 to 3.03; P < .0002; diarrhea—HR = 1.34; 95% CI, 1.08 to 1.66; P < .0009; and grade 2/3 hand-foot-syndrome [HFS]—HR = 3.54; 95% CI, 2.07 to 6.05; P < .00001) were less prominent with FU-based regimens whereas neutropenia (HR = 0.15; 95% CI, 0.11 to 0.19; P < .00001) was lower in the CAP regimens. Conclusion The combination of CAP and OX resulted in lower RR, but this did not affect PFS and OS, which were similar in both treatment arms. The toxicity analysis showed the characteristic toxicity of each of the different FU schedules, with thrombocytopenia and HFS consistently more prominent in the CAP regimens.
Phosphorylation of the Par-1 polarity kinase by protein kinase D regulates 14-3-3 binding and membrane association
Watkins, Janis L., Lewandowski, Katherine T., Meek, Sarah , Störz, Peter , Toker, Alex , Piwnica‐Worms, Helen

Mayo Clinic

Proceedings of the National Academy of Sciences | November 14, 2008 | Volume: 105 | Issue: 47 | Pages: 18378-18383

10.1073/pnas.0809661105 | PMID 19011111 Get It

The Par-1 protein kinases are conserved from yeast to humans, where they function as key polarity determinants. The mammalian Par-1 family is comprised of 4 members (Par-1a, -b, -c, and -d). Previously, we demonstrated that atypical protein kinase C (aPKC) phosphorylates the Par-1 kinases on a conserved threonine residue (T595) to regulate localization and kinase activity. Here, we demonstrate that Par-1b is also regulated by another arm of the PKC pathway, one that involves novel PKCs (nPKC) and protein kinase D. Treatment of cells with the PKC activator phorbol-12-myristate-13-acetate (PMA) potently stimulated phosphorylation of Par-1b on serine 400 (S400), a residue that is conserved in all 4 mammalian Par-1 kinases as well as the fly ortholog. We demonstrate that PMA stimulates nPKC to activate PKD, which in turn directly phosphorylates Par-1b on S400 to positively regulate 14-3-3 binding and to negatively regulate membrane association. Thus, 2 arms of the PKC pathway regulate interactions between Par-1b and 14-3-3 proteins: one involving aPKC and the other nPKC/PKD.
A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics
Sano, Mary , Jacobs, Diane M. , Andrews, Howard, Bell, Karen L. , Graff‐Radford, Neill R. , Lucas, John A. , Rabins, Peter V., Bolla, Karen I., Tsai, Wei-Yan, Cross, Peter, Andrews, Karen L., Costa, Rosann , Luo, Xiaodong

Mayo Clinic

Clinical Trials | September 30, 2008 | Volume: 5 | Issue: 5 | Pages: 523-533

10.1177/1740774508096313 | PMID 18827045 Get It

Background Observational studies and small clinical trials suggested that hormone replacement therapy (HRT) decreases risk of cognitive loss and Alzheimer's disease (AD) in postmenopausal women and may have value in primary prevention. Purpose A clinical trial was designed to determine if HRT delays AD or memory loss. This report describes the rationale and original design of the trial and details extensive modifications that were required to respond to unanticipated findings that emerged from other studies during the course of the trial. Methods The trial was designed as a multi-center, placebo-controlled primary prevention trial for women 65 years of age or older with a family history of dementia. Recruitment from local sites was supplemented by centralized efforts to use names of Medicare beneficiaries. Inclusion criteria included good general health and intact memory functioning. Participants were randomized to HRT or placebo in a 1:1 ratio. Assignment was stratified by hysterectomy status and site. The primary outcomes were incident AD and memory decline on neuropsychological testing. Results Enrollment began in March 1998. In response to the Women's Health Initiative (WHI) May 2002 report of increased incidence of heart disease, stroke, pulmonary embolism, and breast cancer among women randomized to HRT, participants were re-consented with a revised consent form. Procedural modifications, including discontinuation of study medication and a modification of the planned primary outcome based on a final enrollment below the target enrollment (N = 477), were enacted in response to the subsequent WHI Memory Study report of increased risk of dementia and poorer cognitive function with HRT. The mean length of treatment exposure prior to discontinuation was 2.14 years. Participants' mean age at baseline was 72.8; mean education was 14.2 years. Minority participation was 19% and 34% had a hysterectomy. The study continues to follow these participants for a total of 5 years blind to the original medication assignment. Limitations Results reported from the WHI during the course of this study mandated extensive procedural modifications, including discontinuing recruitment before completion and halting study medication. Alternative strategies for study redesign that were considered are discussed. Clinical Trials 2008; 5: 523—533. http://ctj.sagepub.com
Incidence and Risk Factors for Stroke in American Indians
Zhang, Ying , Galloway, James M., Welty, Thomas K. , Wiebers, David O. , Whisnant, Jack P., Devereux, Richard B. , Howard, Barbara V. , Cowan, Linda D., Yeh, Jeunliang, Howard, Wm. James, Lee, Elisa T. , Kizer, Jorge R. , Wang, Wenyu , Best, Lyle G.

Mayo Clinic

Circulation | September 23, 2008 | Volume: 118 | Issue: 15 | Pages: 1577-1584

10.1161/circulationaha.108.772285 | PMID 18809797 Get It

Background— There are few published data on the incidence of fatal and nonfatal stroke in American Indians. The aims of this observational study were to determine the incidence of stroke and to elucidate stroke risk factors among American Indians. Methods and Results— This report is based on 4549 participants aged 45 to 74 years at enrollment in the Strong Heart Study, the largest longitudinal, population-based study of cardiovascular disease and its risk factors in a diverse group of American Indians. At baseline examination in 1989 to 1992, 42 participants (age- and sex-adjusted prevalence proportion 1132/100 000, adjusted to the age and sex distribution of the US adult population in 1990) had prevalent stroke. Through December 2004, 306 (6.8%) of 4507 participants without prior stroke suffered a first stroke at a mean age of 66.5 years. The age- and sex-adjusted incidence was 679/100 000 person-years. Nonhemorrhagic cerebral infarction occurred in 86% of participants with incident strokes; 14% had hemorrhagic stroke. The overall age-adjusted 30-day case-fatality rate from first stroke was 18%, with a 1-year case-fatality rate of 32%. Age, diastolic blood pressure, fasting glucose, hemoglobin A 1c, smoking, albuminuria, hypertension, prehypertension, and diabetes mellitus were risk factors for incident stroke. Conclusions— Compared with US white and black populations, American Indians have a higher incidence of stroke. The case-fatality rate for first stroke is also higher in American Indians than in the US white or black population in the same age range. Our findings suggest that blood pressure and glucose control and smoking avoidance may be important avenues for stroke prevention in this population.
O1‐06–03: Akt functions to regulate the chaperone complex and attenuate Tau degradation
Dickey, Chad A. , Xu, Yafei , Jinwal, Umesh K., Bailey, Rachel M. , Dunmore, Judith, Morgan, Dave, Petrucelli, Leonard , Koren, John , Zhang, Yong‐Jie , Birnbaum, Morris J.

Mayo Clinic

Alzheimer's & Dementia | July 24, 2008 | Volume: 4 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2008.05.258 Get It

Elevation of cAMP in Mesenchymal Stem Cells Transiently Upregulates Neural Markers Rather than Inducing Neural Differentiation
Rooney, Gemma E., Howard, Linda , O’Brien, Timothy , Windebank, Anthony J. , Barry, Frank

Mayo Clinic

Stem Cells and Development | June 13, 2008 | Volume: 18 | Issue: 3 | Pages: 387-398

10.1089/scd.2008.0080 | PMID 18554089 Get It

The aims of this research were to examine the neural expression profile of undifferentiated mesenchymal stem cells (MSCs), to define a serum-free environment that would support the survival of MSCs, and to assess the effects of elevated cyclic adenosine monophosphate (cAMP) levels on MSC morphology and expression of neural markers. The neural profile of MSCs was assessed using immunocytochemistry and real-time polymerase chain reaction (PCR) techniques. These MSCs were then cultured in varying serum-free environments, with flow cytometry analysis of cell viability and apoptosis. The effects of forskolin and 8 bromo-cAMP treatment on MSC morphology and expression of neural markers were assessed using light microscopy, immunocytochemistry and real-time PCR analysis. Expression of the neural markers nestin, vimentin, β III tubulin, glial fibrillary acidic protein, and the tropomyosin-related kinases was demonstrated in normal undifferentiated MSCs. Furthermore, MSCs cultured in serum-free conditions containing ascorbic acid 2-phosphate demonstrated greater long-term survival and reduced apoptosis. In contrast, forskolin increased the percentage of cells undergoing apoptosis. Culture in the presence of forskolin induced a 6-fold increase in β III tubulin expression after a 6-h exposure time, which was accompanied by dramatic changes in morphology. However, this effect was transient, with the cells reverting to their normal morphology by 24 h. Treatment with 8 bromo-cAMP induced similar increases in β III tubulin expression without such dramatic morphological changes. Factors which increase the concentration of cAMP induce transient changes in expression of neural markers that appear to be the result of cellular adaptation to changes in culture conditions rather than a real process of neural differentiation.